Skip to main content
. 2022 Dec 15;14(24):6209. doi: 10.3390/cancers14246209

Table 1.

Overview of patient characteristics.

No Figure Age Tumor Location Tumor Differentiation cTNM Stage * pTNM Stage Max Diameter (mm) ** SUVmax [18F]DCFPyL SUVmax [18F]FDG TBR [18F]DCFPyL TBR [18F]FDG H-Score
1 72 Colon adenocarcinoma Well/moderate cT3/4N1M0 pT3N0M0 180 9.9 45.5 7.3 20.4 120
2 68 Colon adenocarcinoma Well/moderate cT4N2M0 pT4N0M0 80 1.9 29.1 2.3 15.6 225
3 73 Colon adenocarcinoma Poor cT4N0M0 pT4N0M0 50 3.3 22.5 2.4 14.1 60
4 58 Colon adenocarcinoma Well/moderate cTxN0M0 pT4N0M0 15 1.5 4.5 1.2 1.7 80
5 38 Signet ring cell gastric carcinoma Poor cT2-3N0M0 ypT3N0M0 42 3.5 n.a. 1.9 n.a. 0
6 71 Tubular gastric adenocarcinoma Moderate cT4N1M0 ypT3N1M0 25 2.5 7.8 2.3 2.9 150
7 50 Tubular gastric adenocarcinoma Poor cT3N0M0 ypT4N1M0 45 2.1 4.4 1.4 1.6 0
8 70 PDAC Well cTxN0M0 pT2N1M0 22 3.3 3.6 2.0 1.3 150
9 76 PDAC Moderate cTxN0M0 pT2N1M0 28 2.4 6.8 2.0 4.3 30
10 63 PDAC Well cTxN2M0 pT2N2M0 35 5.1 10.1 2.8 3.9 0

Abbreviations: TNM stage, tumor, nodal and metastatic status; SUV, standardized uptake value; n.a., not available; H-score, immunohistochemical staining score; PDAC, pancreatic ductal adenocarcinoma. * Pathological TNM stage for colon and pancreatic cancer patients, initial clinical TNM stage for gastric cancer patients (as neoadjuvant therapy was given after [18F]DCFPyL PET/CT). ** Diameter measured at pathological examination.